
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72246
10.1038/s41598-024-72246-w
Article
Impact of diet intervention on visceral adipose tissue and hepatic fat in patients with obesity or type 2 diabetes: a randomized trial
Krittayaphong Rungroj sirktt@gmail.com

1
Treesuwan Witcha 2
Pramyothin Pornpoj 3
Songsangjinda Thammarak 4
Kaolawanich Yodying 1
Srivanichakorn Weerachai 5
Jangtawee Preechaya 1
Yindeengam Ahthit 6
Tanapibunpon Prajak 6
Vanavichit Apichart 7
1 https://ror.org/01znkr924 grid.10223.32 0000 0004 1937 0490 Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok, 10700 Thailand
2 https://ror.org/05gzceg21 grid.9723.f 0000 0001 0944 049X Department of Nutrition and Health, Institute of Food Research and Product Development, Kasetsart University, Bangkok, Thailand
3 https://ror.org/01znkr924 grid.10223.32 0000 0004 1937 0490 Division of Nutrition, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
4 https://ror.org/0575ycz84 grid.7130.5 0000 0004 0470 1162 Division of Internal Medicine, Faculty of Medicine, Cardiology Unit, Prince of Songkla University, Songkhla, Thailand
5 https://ror.org/01znkr924 grid.10223.32 0000 0004 1937 0490 Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
6 grid.416009.a Her Majesty Cardiac Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand
7 https://ror.org/05gzceg21 grid.9723.f 0000 0001 0944 049X Rice Science Center, Kasetsart University, Kamphangsaen, Nakhon Pathom, Thailand
13 9 2024
13 9 2024
2024
14 213882 2 2024
5 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This study aimed to assess the effects of a diet intervention on visceral and hepatic fat in patients with obesity or type 2 diabetes (T2D). Participants with obesity or T2D were randomized to a diet intervention or their usual diet. The intervention comprised a “3G rice” regimen combined with a low-salt, high-fiber diet. The primary outcomes were changes in visceral adipose tissue (VAT) area and hepatic fat over 12 weeks assessed by magnetic resonance imaging. Eighty-six patients were randomized. Their mean age was 47.5 ± 11.0 years, and 82.3% were female. Eighty-one (94.2%) had obesity, and 16 (18.6%) had T2D. Baseline metrics were body weight 76.3 ± 16.1 kg, BMI 29.6 ± 4.6, VAT 12 629 ± 5819 mm2, and hepatic fat 7.9% ± 7.2%. At the 12-week follow-up, the diet group had greater VAT and hepatic fat reductions than controls (− 1468 ± 1468 vs. − 179 ± 1576 mm2, P = 0.001; and − 2.6% ± 3.4% vs. 0.4% ± 2.2%, P < 0.001). Adjusted differences remained significant for VAT (− 1093 mm2, P < 0.001) and hepatic fat (− 2.5%, P < 0.001). In conclusion, the 12-week diet intervention decreased VAT, hepatic fat, body weight, and BMI compared to a usual diet.

Keywords

Diabetes
Diet intervention
Hepatic fat
Obesity
Visceral fat
Subject terms

Type 2 diabetes
Obesity
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Type 2 diabetes (T2D) and obesity is a significant risk factor for atherosclerotic disease, particularly when visceral adipose tissue (VAT) accumulation is involved1,2. Elevated VAT levels have been associated with endothelial dysfunction, inflammatory markers, and incident cardiovascular disease3. This metabolic risk is evident even in patients with normal body weight4. Hepatic fat also contributes to cardiovascular risk and insulin resistance5,6.

Numerous interventions have been employed to manage obesity and T2D, with the objective of mitigating their complications2. However, certain drugs may pose potential dangers such as rosiglitazone for T2D and sibutramine for weight reduction in obesity7,8. Furthermore, the costs of medications and treating disease-related complications impose significant financial burdens in low- and middle-income countries9. Therefore, lifestyle and dietary changes remain fundamental recommendations in major practice guidelines for managing obesity and T2D. Lifestyle interventions have shown considerable efficacy in preventing and controlling T2D10,11. Demographic factors, dietary patterns and physical activity levels were found to be associated to abdominal obesity.. A previous study demonstrated that the risk of visceral fat decreased with an increased consumption of fruit and vegetable and decreased consumption of carbohydrate12. The Mediterranean diet, characterized by low in animal protein and saturated fats, high in fibers and antioxidants, and with an omega-3 to omega-6 fatty balance, has been suggested to be effective in the prevention and management of fatty liver13 with some supporting evidence for the management of abdominal fat14. However, adherence to Mediterranean diet cannot be demonstrated to have effect on the prevention or changes of abdominal obesity15. Among 13 clinical trials evaluated the effect of Mediterranean diet plus caloric restriction, only 3 of them demonstrated beneficial effect of the intervention group compared to the control group14. Some of these studies also included lifestyle modification mainly increased physical activity. They mentioned that the effect of diet pattern on visceral fat may be varied which is influenced by the degree of physical activity and age group of the study population12,14–16. Therefore, their impact on reducing cardiovascular risk requires further investigation17. Diet interventions, such as reducing high glycemic index (GI) carbohydrate consumption, implementing caloric control, and increasing vegetable and fruit intake, are effective in improving control of obesity and T2D and reducing complications10. Dietary changes and physical activity can also lower the risk of developing T2D and its complications18. A Korean study indicates that healthy subjects who are in the top 10th percentile of visceral fat had a higher risk of T2D and prediabetes with the Odds ratio of 15.919. Reduction in visceral fat and hepatic fat has been shown to be associated with the reduction in cardiovascular risk20,21.

The 3G rice used in this study is a blend of 3 rice varieties in a 1:1:1 ratio. It comprises 2 soft-cooked, whole grain, intermediate GI rice varieties (“Riceberry,” a high-antioxidant purple rice, and “Hom Malaiman,” an aromatic brown rice) and the low GI rice “Pink + 4” (a hard-cooked, fragrant white rice with high amylose content)22. This combination enhances the soft-fluffiness and the dietary fiber content of 3G rice when cooked. The GI of the rice, determined through tests conducted at the Food Innovation and Resource Centre, Singapore Polytechnic, Singapore, is 5223.

This research utilized magnetic resonance imaging (MRI) to evaluate the impact of diet intervention on visceral and hepatic fat, key indicators of cardiovascular risk, in patients with obesity or T2D.

Results

Study population

Out of 121 screened patients, 86 were randomized, with 43 individuals allocated to the diet intervention group and 43 to the usual diet group. During the study period, 6 patients from the usual diet group withdrew, and 1 patient was lost to follow-up. A total of 43 patients in the diet intervention group and 36 in the usual diet group completed the 12-week follow-up visit (Fig. 1). Their mean age was 47.5 ± 11.0 years (range 30–72 years), and 17.7% of the participants were male. Number of patients with obesity was 41 (95.3%) in diet intervention group and 40 (93.0%) in usual diet group. BMI was 30.1 ± 5.2 in the diet intervention group and 29.1 ± 4.0 in the usual diet group (p = 0.324).Fig. 1 CONSORT diagram of the study population.

Table 1 details the baseline characteristics of patients in both groups. No significant differences were observed in their characteristics. Baseline hepatic fat was 7.9 ± 7.2% and baseline visceral adipose tissue was 12 629 ± 5819 mm2. Hepatic fat was classified as normal, mild, moderate, and severe in 51 (59.3%), 25 (29.1%), 4 (4.7%), and 6 (7.0%), respectively. Table 1 Baseline characteristics of patients in the diet intervention and usual diet groups.

	All	Diet intervention	Usual diet	
(n = 86)	(n = 43)	(n = 43)	
Age (y)	48.0 ± 11.5	46.5 ± 10.5	49.5 ± 12.4	
Male sex, n (%)	16 (18.6%)	9 (20.9%)	7 (16.3%)	
Body weight (kg)	76.3 ± 16.1	78.2 ± 18.6	74.4 ± 13.3	
BMI (kg/m2)	29.6 ± 4.6	30.1 ± 5.2	29.1 ± 4.0	
BMI ≥ 25 kg/m2	81 (94.2%)	41 (95.3%)	40 (93.0%)	
Type 2 diabetes	16 (18.6%)	7 (16.3%)	9 (20.9%)	
Systolic blood pressure (mmHg)	137.5 ± 18.0	137.6 ± 17.5	137.4 ± 18.6	
Diastolic blood pressure (mmHg)	80.0 ± 9.7	79.1 ± 10.1	80.8 ± 9.2	
Heart rate (bpm)	79.7 ± 12.4	81.7 ± 12.4	77.6 ± 12.2	
Fasting plasma glucose (mg/dl)	94.7 ± 23.9	92.8 ± 15.1	96.7 ± 30.3	
HbA1C (%)	6.1 ± 0.9	6.0 ± 0.7	6.1 ± 1.1	
Total cholesterol (mg/dl)	201.0 ± 36.1	198.4 ± 30.4	203.5 ± 41.3	
Triglyceride (mg/dl)	129.6 ± 78.5	114.8 ± 42.0	144.3 ± 101.3	
HDL (mg/dl)	54.9 ± 12.5	53.5 ± 9.9	56.2 ± 14.7	
Calculated LDL (mg/dl)	120.2 ± 33.2	122.0 ± 27.0	118.4 ± 38.7	
AST (U/L)	23.8 ± 12.5	22.5 ± 11.9	25.1 ± 13.0	
ALT (U/L)	25.0 ± 19	26.1 ± 22.7	24.0 ± 14.6	
Alkaline phosphatase (U/L)	71.9 ± 19.3	73.2 ± 20.2	70.6 ± 18.5	
Albumin (g/dl)	4.8 ± 2.5	5.1 ± 3.4	4.4 ± 1	
Serum creatinine (mg/dl)	0.7 ± 0.2	0.7 ± 0.2	0.7 ± 0.2	
Sodium (mmol/L)	139.9 ± 2.2	140 ± 2.5	139.8 ± 2	
Potassium (mmol/L)	4.0 ± 0.7	3.9 ± 0.7	4.0 ± 0.8	
Uric acid (mg/dl)	5.3 ± 1.2	5.2 ± 1.2	5.4 ± 1.1	
Hs-CRP (mg/L)	4.4 ± 7.1	5.4 ± 9.5	3.4 ± 3.2	
Urine albumin/Urine Cr (mg/g.cr)	19.8 ± 45.9	27.8 ± 61.3	11.9 ± 19.3	
Body fat mass (%)	38.7 ± 6.5	39.5 ± 5.4	37.9 ± 7.4	
Visceral adipose tissue area (mm2)	12 629.0 ± 5818.6	13 001.3 ± 5586.3	12 256.6 ± 6084.9	
Hepatic fat (%)	7.9 ± 7.2	8.6 ± 7.8	7.2 ± 6.5	
Data are presented as the means (± SD) for continuous variables or as frequencies and percentages for categorical variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein cholesterol.

Study outcomes

Table 2 displays the changes in clinical parameters, laboratory results, VAT area, and hepatic fat percentage between the baseline and 12-week follow-up visits for the 2 groups. Patients in the diet intervention group demonstrated significant reductions in body weight, BMI, waist circumference, VAT area, and hepatic fat percentage compared to the usual diet group. Figure 2 depicts the changes from baseline to 12 weeks in body weight, BMI, VAT area, and hepatic fat using vertical scattered plots. The diet intervention group exhibited a greater reduction in the primary outcome variables than the usual diet group (P < 0.001 for all). Table 2 Changes in clinical parameters, laboratory values, and measurement outcomes of patients with diet intervention and usual diet.

	All	Diet intervention	Usual diet	P*	
(n = 79)	(n = 43)	(n = 36)	
Body weight (kg)	 − 2.0 ± 2.5	 − 2.9 ± 2.6	 − 0.8 ± 1.8	 < 0.001	
BMI (kg/m2)	 − 0.8 ± 0.9	 − 1.1 ± 1.0	 − 0.3 ± 0.7	 < 0.001	
Waist circumference (cm)	 − 2.4 ± 6.0	 − 3.9 ± 6.2	 − 0.6 ± 5.3	0.013	
Hip circumference (cm)	 − 2.8 ± 4.7	 − 3.6 ± 4.9	 − 1.8 ± 4.5	0.103	
Systolic blood pressure (mmHg)	0.4 ± 15.4	 − 0.5 ± 17.2	1.4 ± 13.2	0.573	
Diastolic blood pressure (mmHg)	 − 0.6 ± 10.2	 − 1.2 ± 10.0	0.2 ± 10.6	0.554	
Heart rate (bpm)	 − 3.4 ± 12.1	 − 5.1 ± 12.6	 − 1.4 ± 11.4	0.176	
Fasting plasma glucose (mg/dl)	 − 0.4 ± 12.6	 − 1.8 ± 13.7	1.3 ± 11.1	0.277	
HbA1C (%)	 − 0.1 ± 0.5	 − 0.2 ± 0.6	0.01 ± 0.3	0.137	
Total Cholesterol (mg/dl)	 − 6.3 ± 31.5	 − 6.2 ± 39.4	 − 6.3 ± 18.8	0.992	
Triglyceride (mg/dl)	 − 8.5 ± 52.4	 − 7.2 ± 40.7	 − 10.1 ± 64.3	0.810	
HDL (mg/dl)	0.4 ± 7.0	0.1 ± 6.3	0.8 ± 7.9	0.655	
Calculated LDL (mg/dl)	 − 2.7 ± 22.0	 − 0.6 ± 22.8	 − 5.2 ± 21.1	0.361	
AST (U/L)	 − 3.1 ± 10.4	 − 2.0 ± 10.1	 − 4.3 ± 10.7	0.322	
ALT (U/L)	 − 3.3 ± 10.5	 − 3.8 ± 10.7	 − 2.6 ± 10.4	0.623	
Alkaline phosphatase (U/L)	 − 1.3 ± 8.8	 − 1.6 ± 9.8	 − 0.8 ± 7.4	0.691	
Albumin (g/dl)	0.5 ± 5.5	 − 0.3 ± 3.9	1.6 ± 6.8	0.129	
Serum creatinine (mg/dl)	0.01 ± 0.1	0.01 ± 0.1	 − 0.01 ± 0.1	0.187	
Sodium (mmol/L)	0.4 ± 2.3	0.6 ± 2.3	0.2 ± 2.2	0.498	
Potassium (mmol/L)	 − 0.3 ± 0.8	 − 0.2 ± 0.7	 − 0.3 ± 0.9	0.790	
Uric acid (mg/dl)	0.01 ± 0.8	0.1 ± 1.0	 − 0.1 ± 0.6	0.175	
Hs-CRP (mg/L)	 − 0.8 ± 3.2	 − 0.9 ± 4.1	 − 0.6 ± 1.8	0.674	
Urine albumin/Urine Cr (mg/g.cr)	1.3 ± 19.1	 − 0.2 ± 23.4	3.0 ± 12.3	0.482	
Body fat mass (%)	 − 1.4 ± 4.3	 − 2.6 ± 4.0	0.1 ± 4.2	0.006	
Visceral adipose tissue area (mm2)*	 − 836.2 ± 1623.9	 − 1467.9 ± 1467.6	 − 179.4 ± 1575.7	0.001	
Hepatic fat (%)*	 − 1.3 ± 3.3	 − 2.6 ± 3.4	0.4 ± 2.2	 < 0.001	
Data are presented as the means (± SD).

Bold indicates statistical significance.

*Adjusted p-value for multiple comparisons at p < 0.025.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein cholesterol.

Fig. 2 Scatter plot of changes from baseline to 12 weeks in (A) body weight (B) body mass index (BMI) (C) visceral adipose tissue (VAT) and (D) hepatic fat. Adjusted p-value for multiple comparisons at p < 0.025 for VAT and hepatic fat.

Both groups experienced a significant reduction in body weight and BMI (Table 3). However, the extent of body weight reduction was greater in the diet intervention group than in the usual diet group (2.9 ± 2.6 vs. 0.8 ± 1.8 kg, P < 0.001; Table 2). Similarly, BMI reduction was greater in the diet intervention group (1.1 ± 1.0 vs. 0.3 ± 0.7 kg/m2, P < 0.001; Table 2). However, there was a significant reduction in VAT area and hepatic fat only in the diet intervention group. The diet intervention group showed a VAT area reduction of 1467.9 ± 1467.6 mm2, whereas the usual diet group exhibited a reduction of 179.4 ± 1575.7 mm2 (P = 0.001 for the difference between groups). The diet intervention group had a hepatic fat reduction of 1.6% ± 3.4%, while the usual diet group experienced an increase in hepatic fat of 0.4% ± 2.2% (P < 0.001). Figure 3 presents an example of a patient in the diet intervention group. It demonstrates significant changes in the VAT area and hepatic fat percentage. Table 3 Comparisons of body weight, body mass index (BMI), visceral adipose tissue (VAT) area, and hepatic fat at baseline and 12 weeks in the diet intervention and usual diet groups.

	Baseline	3 months	P*	Change	
All	
Body weight (kg) (n = 79)	77.1 ± 15.6	75.1 ± 15.7	 < 0.001	 − 2.0 ± 2.5	
BMI (kg/m2) (n = 79)	30.0 ± 4.7	29.2 ± 4.8	 < 0.001	 − 0.8 ± 0.9	
Body fat mass (%) (n = 79)	39.4 ± 5.8	38.1 ± 6.0	0.006	 − 1.4 ± 4.3	
Visceral adipose tissue (mm2) (n = 79)	12 463.6 ± 5209.3	11 627.3 ± 4892	 < 0.001	 − 836.2 ± 1623.9	
Hepatic fat (%) (n = 79)	8.2 ± 7.5	6.9 ± 6.3	0.001	 − 1.3 ± 3.3	
Native T1 value (whole LV segment) (n = 78)	1263.3 ± 35.3	1265.3 ± 32.8	0.494	2.0 ± 26.2	
	Baseline	3 months	P	Change	
Diet intervention	
Body weight (kg) (n = 43)	79.7 ± 18.0	76.7 ± 18.2	 < 0.001	 − 2.9 ± 2.6	
BMI (kg/m2) (n = 43)	30.5 ± 5.1	29.4 ± 5.2	 < 0.001	 − 1.1 ± 1.0	
Body fat mass (%) (n = 43)	39.8 ± 5.3	37.3 ± 6.3	 < 0.001	 − 2.6 ± 4	
Visceral adipose tissue (mm2) (n = 43)	13 007.7 ± 5574.2	11 621.6 ± 5106.7	 < 0.001	 − 1386.2 ± 1465.9	
Hepatic fat (%)(n = 43)	9.3 ± 8.2	6.6 ± 5.8	 < 0.001	 − 2.7 ± 3.4	
Native T1 value (whole LV segment) (n = 42)	1252.8 ± 37.2	1259.6 ± 26.8	0.126	6.8 ± 28.2	
Usual diet	
Body weight (kg) (n = 36)	73.9 ± 11.7	73.1 ± 12.2	0.011	 − 0.8 ± 1.8	
BMI (kg/m2) (n = 36)	29.3 ± 4.0	28.9 ± 4.3	0.010	 − 0.3 ± 0.7	
Body fat mass (%) (n = 36)	39.0 ± 6.4	39.0 ± 5.5	0.933	0.1 ± 4.2	
Visceral adipose tissue (mm2) (n = 36)	11 813.6 ± 4731.9	11 634.2 ± 4694.6	0.499	 − 179.4 ± 1575.7	
Hepatic fat (%)(n = 36)	6.9 ± 6.5	7.3 ± 6.9	0.343	0.4 ± 2.2	
*Bold, statistical significance.

Fig. 3 An example image presenting visceral adipose tissue (VAT) and hepatic fat changes of a patient in the diet intervention group with a significant reduction in VAT area and % hepatic fat (HF). Color scale indicates % hepatic fat. (A) baseline (B) after diet intervention.

Linear regression analysis, adjusted for baseline data of each outcome, indicated that diet intervention was significantly associated with reductions in body weight, BMI, VAT area, and hepatic fat relative to the usual diet group. Figure 4A,B illustrates the effects of diet intervention on body weight, BMI, VAT, and hepatic fat percentage as a forest plot of adjusted differences between groups (diet intervention and usual diet) from multiple regression analysis.Fig. 4 Effect of diet intervention on body weight (BW), body mass index (BMI), body fat mass, visceral adipose tissue, and hepatic fat shown as a forest plot of adjusted differences between groups (diet intervention and normal diet) from multiple regression analysis. (A) adjusted for baseline (B) adjusted for baseline, age, sex, and body mass index. Adjusted p-value for multiple comparisons at p < 0.025 for VAT and hepatic fat.

Comparison of physical activity levels of patients in diet intervention and usual diet group demonstrated that patients win the usual diet group had more duration of moderate intensity (89.9 ± 111.4 vs. 154.4 ± 125.1 min per week, p = 0.018), similar level of vigorous intensity (17.7 ± 36.5 vs. 19.0 ± 31.9 min per week, p = 0.871), and step count (5868 ± 3171 vs. 5341 ± 2694 steps per day, p = 0.434).

Sensitivity analysis

The sensitivity analysis on the interaction of obesity and diabetes on the study outcomes was to determine whether the effect of diet intervention on changes in visceral fat and hepatic fat was consistent for both obesity and T2D group or not. The results indicated that there was no significant interaction (interaction p = 0.854 for visceral fat change and p = 0.611 for hepatic fat change).

To assess the impact of the intervention, we compared the changes in the grading of hepatic fat. Specifically, we examined the proportion of patients in each group who experienced a reduction of at least 1 grade in VAT and hepatic fat. Among the 33 patients with abnormal hepatic fat at baseline (classes 2–4), 60% (12 patients) in the diet intervention group achieved a decrease of at least 1 class in hepatic fat, whereas only 7.7% (1 patient) in the usual diet group showed a similar improvement (P = 0.003).

We analyzed the percentage changes in the clinical outcome variables to determine whether the changes in body weight influenced those in the VAT area and hepatic fat. The results revealed that the percentage changes in VAT area and hepatic fat in the diet intervention group exceeded the percentage changes in body weight and BMI compared to the usual diet group (Table 4). Table 4 Percentage change in selected parameters between patients in the diet intervention and usual diet groups.

	All	Diet intervention	Usual diet	P*	
(n = 79)	(n = 43)	(n = 36)		
Body weight (kg)	 − 2.8 ± 3.6	 − 4 ± 3.6	 − 1.4 ± 3.2	0.001	
BMI (kg/m2)	 − 2.6 ± 3.3	 − 3.8 ± 3.2	 − 1.2 ± 2.9	0.001	
Body fat mass (%)	 − 2.6 ± 15.6	 − 6.4 ± 10.1	2.0 ± 19.6	0.017	
Visceral adipose tissue (mm2)*	 − 6.1 ± 14.3	 − 10.3 ± 10.9	 − 1.1 ± 16.3	0.006	
Hepatic fat (%)*	 − 8.4 ± 43.1	 − 22.9 ± 32.8	8.9 ± 47.9	0.001	
Percentage change = ([12 week data − baseline data]/baseline data) × 100.

Bold indicates statistical significance.

*Adjusted p-value for multiple comparisons at p < 0.025.

We performed additional analysis on the changes of visceral fat and hepatic fat with the adjustment of body weight change. The results showed that the effect of diet intervention on hepatic fat reduction remained significant with the adjusted reduction of − 2.51% (− 3.95 to − 1.07%), p = 0.001 and borderline significant for visceral fat reduction, − 654 mm2 (− 1354 to 46 mm2), p = 0.067.

We also analyzed the data on actual caloric intake and composition at baseline 12-week and changes. The results are shown in Table 5. Patients with diet intervention had a significant reduction in total calories as well as calories from carbohydrate and fat but the calories from protein significantly increased. Table 5 Data on actual caloric intake and composition at baseline 12-week and change from baseline to 12-week.

	Diet intervention (n = 43)	Usual diet (n = 36)	P	
Baseline	
 Total calories	2116.8 ± 393.0	2161.1 ± 206.1	0.544	
 Calories from carbohydrate	1164.2 ± 216.2	1188.6 ± 113.4	0.524	
 Calories from protein	317.5 ± 59.0	324.2 ± 30.9	0.439	
 Calories from fat	635.0 ± 117.9	648.3 ± 61.8	0.650	
12-week	
 Total calories	1476.4 ± 267.8	1945.0 ± 185.5	 < 0.001	
 Calories from carbohydrate	850.1 ± 194.1	992.7 ± 94.7	 < 0.001	
 Calories from protein	397.1 ± 52.1	370.7 ± 35.4	0.009	
 Calories from fat	229.0 ± 32.6	581.6 ± 54.5	 < 0.001	
Change (Baseline-12 week)	
 Total calories	 − 640.5 ± 250.7	 − 216.1 ± 20.6	 < 0.001	
 Calories from carbohydrate	 − 314.1 ± 152.0	 − 195.9 ± 18.7	 < 0.001	
 Calories from protein	79.7 ± 37.9	46.6 ± 4.4	 < 0.001	
 Calories from fat	 − 406.0 ± 94.3	 − 66.8 ± 6.4	 < 0.001	

Compliance and satisfaction with diet intervention

Compliance with the diet intervention was assessed through a questionnaire. The results revealed that 32.6% (14 patients) reported 100% compliance without consuming extra snacks, 60.5% (26 patients) achieved ≥ 90% compliance, and 83.7% (36 patients) achieved ≥ 80% compliance.

Satisfaction with the diet intervention was also evaluated via a questionnaire. The participants rated various aspects on a scale from 1 to 5, with 5 indicating the highest level of satisfaction and 1 indicating the lowest. Participants expressed satisfaction with the diet intervention. Specifically, they rated it favorably in terms of health benefits (4.3 ± 0.6), color (4.1 ± 0.8), appearance (4.0 ± 0.8), odor (4.0 ± 0.6), taste (4.0 ± 0.8), cleanness (4.0 ± 0.8), amount (3.8 ± 0.9), diversity (3.6 ± 0.7), and softness (3.6 ± 1.0).

Discussion

This is a randomized clinical study comparing diet intervention with usual diet for 12 weeks. Low caloric diet was applied in both groups. The 12-week diet intervention resulted in greater visceral and hepatic fat reductions than those in the usual diet group. Additionally, patients in the diet intervention group experienced larger body weight, BMI, and total body fat mass reductions than those in the usual diet group. While patients in the usual diet group experienced significant reductions in body weight and BMI, there was no corresponding significant decrease in their VAT and hepatic fat. Despite the greater body weight reduction in diet intervention group, the main results on the reduction of hepatic fat and VAT were mainly preserved after the adjustment of body weight change.

Numerous studies have highlighted the link between visceral fat, hepatic fat, and cardiovascular disease3,4,24. Increased levels of VAT and hepatic fat can lead to endothelial dysfunction25 and elevated inflammatory markers26, contributing to atherosclerotic disease1,6. These effects are particularly pertinent in Asian populations. Previous research has shown that increased VAT is associated with metabolic risk factors in the Japanese population, even among individuals with normal body weight4. Moreover, the prevalence of abdominal obesity in Asian Indians is approximately 70%, which exceeds the prevalence of obesity defined by BMI27. At any given BMI, Asian Indians tend to have more abdominal obesity, insulin resistance, hyperinsulinemia, hypertension, and diabetes than Caucasians26,28.

Adopting a healthy diet and engaging in physical fitness can promote reductions in body weight and visceral fat16. The Mediterranean diet, rich in fiber from fruits, vegetables, legumes, and whole grains while limiting foods high in saturated and trans fats (e.g., fatty meats and highly processed foods), has been associated with lower abdominal fat gain over 10 years in the Spanish population29. However, the impact of the Mediterranean diet on the incidence of abdominal obesity remains inconclusive. The AdolesHealth study on European adolescents indicated that adherence to the Mediterranean diet did not influence waist circumference or body fat changes based on bioimpedance measurements15. A systematic review assessing the effects of the Mediterranean diet on central obesity demonstrated that 13 out of 18 studies showed a significant reduction in central obesity14. The explanation for the inconsistent results of healthy diet on VAT among many studies may be related to the characters and age group of study population, type of intervention, and degree of physical activity. Our study included participants with obese or T2D and record their physical activity. We tested the interaction of obese and T2D on study outcome and showed that there were no significant interactions. Therefore, the results of our study indicate the health benefit of diet intervention based on a low glycemic index, high fiber and low sodium. Mediterranean diet that is claimed to be rich in fiber had the fiber content of approximately 14 g per 100 kcal30 which is equivalent to the fiber in the food tat we provided to the participants in the diet intervention arm. Diet with high fiber promote benefits in the reduction of risk of T2D, visceral fat, gut microbial variability, and reduction of systemic inflammation31. Based on the result of a previous study, daily sodium content of the Mediterranean diet32 is higher than the sodium content of diet intervention arm in our study. Besides, the low glycemic index carbohydrate used in the diet intervention group of our study promote the health benefits of patients with obesity and T2D33.

We analyzed the percentage change in clinical outcomes to examine whether the reduction in VAT area and hepatic fat could be attributed solely to changes in body weight. The results indicated that the diet intervention group exhibited a more substantial percentage change in VAT area and hepatic fat than the percentage change in body weight and BMI seen in the usual diet group. This finding suggests that the diet intervention had a more pronounced effect on reducing VAT and hepatic fat beyond weight reduction alone. Besides, we performed additional analysis on the changes of visceral fat and hepatic fat with the adjustment of body weight change. The results showed that the effect of diet intervention on hepatic fat and VAT reduction remained the similar.

It is crucial to emphasize that obesity treatment should not solely focus on weight reduction. Instead, equal attention should be given to reducing visceral and hepatic fat, as they are associated with cardiovascular disease to a greater extent than BMI and other types of adipose tissue24,34. Our study demonstrated that while there was a reduction of − 0.8 ± 1.8 kg in body weight in the usual diet group, it did not lead to a significant decrease in VAT and hepatic fat. Conversely, the diet intervention group showed greater reductions in hepatic and visceral fat alongside weight reduction than the usual diet group. This disparity might be due to a need for more substantial weight loss to observe significant effects on visceral and hepatic fat. An alternative explanation could be that 3G rice has additional beneficial effects on individuals’ metabolic profiles beyond weight reduction alone. Further research is warranted to verify this concept and provide conclusive evidence on the effect of specific diets on VAT and hepatic fat reduction. We believed that nutritional counseling may have some impact on weight reduction since participants in usual diet group.

Mediterranean diet has a high proportion of nuts, legumes, olive oil, fruit and vegetables, cereals, fish, monounsaturated fatty acid/saturated fatty acid (MUFA:SFA) ratio, moderate consumption of dairy products and wine, and low consumption of meat and meat products35. It has been shown that Mediterranean diet is associated with a reduction in cardiovascular risk and a lower rate of mortality in patients with cardiovascular disease36. 3G rice has been developed with the purpose on the low glycemic property23. Besides, it has the antioxidant property and the softness in the texture22. Due to the high fiber content of Mediterranean diet and 3G rice, the absorption of glucose is lower and slower. Low glycemic index is the main action of benefit of 3G rice. The main glucose benefit of the Mediterranean diet is by the improvement of insulin sensitivity35. In fact, the component of the Mediterranean diet may be low glycemic index or high glycemic index which has differential effect on the glucose absorption37. Since some components of Mediterranean diet are limited availability in many Asian countries and are considered costly. Moreover, alcoholic intake using wine is restricted in many Asian groups. 3G rice may be more suitable in population who live in the countries with rice is the main component of carbohydrate in the diet.

Intermittent fasting is another method of diet intervention in patients with obesity or T2D38,39. The benefit of intermittent fasting is related to the benefit on the weight reduction. However, it is difficult to maintain in the long time39. In an meta-analysis, intermittent fasting can reduce body weight and BMI compared to control and compared to caloric restriction. Intermittent fasting but did not significantly affect fat mass, lean body mass, visceral fat, insulin, HbA1c, lipid profiles or blood pressure38. It has benefit on fasting glucose when compared to control but no benefit when compared to caloric restriction38. Moreover, recent study link intermittent fasting with a 91% increase risk of cardiovascular death40. Therefore, we believed that 3G rice with caloric restriction would be suitable for the countries where rice is the main resource of carbohydrate.

Several limitations should be considered in interpreting the study results. First, we only reported intermediate-term results after 12 weeks of diet intervention. Consequently, there are no data on the intervention’s long-term effects. Second, the study did not demonstrate the effects of diet intervention on traditional cardiovascular risk factors, such as serum glycemic levels or lipid profiles. These effects might need more extended follow-up periods to be observed. Third, participants in the usual diet group also experienced significant reductions in body weight and BMI, possibly influenced by the nutritionists’ diet and exercise education during the study period. However, the diet intervention group showed larger body weight and BMI reductions than the usual diet group. It seems to be a limitation that the control group only is subjected to a relatively limited intervention. We realized that the study could be performed by the assessment of the intervention in all patients without the control group. But we intended to have the control group for the comparative purpose and for the demonstration of the effect of intervention in comparison to usual diet. Fourth, the drop-out rate in the non-intervention group was 7 in the usual diet group (16%) vs none in the intervention group (0%). The drop-out in the usual diet group might be related to their expectation to receive diet intervention from randomization. When they were randomized into usual diet group, their willingness to remain in the study is lost. We also analyzed the data of the participants who withdrew from the study or lost to follow-up and found that the demographic and baseline data were similar to the main study population. Therefore, the drop-out should not have much effect on the results of the study. Fifth, the benefit of diet intervention group is not only from 3G rice. Diet intervention also include high fiber, low sodium diet, increased consumption of fruits and vegetables and a negative caloric balance. So there are multiple interventions towards reduction of VAT and hepatic fat. Sixth, female accounts for 82.3% of the study population which may limit the generalizability of the findings. Seventh, we provided diet for the diet intervention group but the food was provided to the usual diet group. We believed that participants who were randomized to usual diet group should continue taking their own usual diet. If we try to provide diet to the usual diet group it might not reflect the usual diet. However, we have recorded food intake in the food diary before and during the study period in the control arm and record the extra food intake in the intervention arm. We also analyze the food content and caloric intake of both groups before and during the study. Finally, there might be discrepancy in behavior could be influenced by participants’ expectations of being assigned to the diet intervention group, potentially introducing bias in the behavior of the usual diet group participants.

In conclusion, the 12-week diet intervention effectively reduced VAT, hepatic fat, body weight, and BMI compared to the usual diet. While the usual diet group also experienced a significant reduction in body weight and BMI, it did not show a corresponding reduction in VAT and hepatic fat. Notably, the diet intervention group achieved greater body weight and BMI reductions than the usual diet group. These findings underscore the importance of addressing visceral and hepatic fat reduction alongside weight reduction in the management of obesity and its associated cardiovascular risks.

Materials and methods

Study population

The study included patients aged 30–80 with obesity or T2D. We studied subjects with age between 30 and 80 based on the increased risk of visceral and hepatic fat increased after age 30 and continue to the 7th decade of 200% in male and 400% in female41,42. The exclusion criteria were as follows: (1) current or recent hospitalization within the past 3 months; (2) allergy to 3G rice or its components; (3) regular consumption of 3G rice or related products; (4) chronic kidney disease stage IV–V; (5) pregnancy or breastfeeding; and (6) inability to comply with the study protocol, such as inaccurately recording food diaries. The Institutional Review Board of Siriraj Hospital authorized the study protocol (approval number Si 778/2021). The trial was registered with the Thai Clinical Trials Registry (registration number TCTR20211207003; 07/12/2021). Prior to participation, all individuals provided written informed consent. The methodology was this study was in accordance with the principles set forth in the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice Guidelines. Sample size was calculated from a previous study43 the expected reduction in visceral fat of − 16 ± 2 cm2 in intervention arm and − 5 ± 3 cm2 in usual diet arm. The assumption was based on the power of 90% and a significant level at 0.05. The enrollment started January 2022 and the follow-up was conducted through January 2023. The trial was stopped after complete the funding period.

Due to differing associations between body mass index (BMI) and health risks in Asian populations compared to Europeans, this study adopted the obesity definitions for Asians recommended by the International Obesity Task Force in 2000. “Overweight” was defined as a BMI ≥ 23 kg/m2, and “obesity” was defined as a BMI ≥ 25 kg/m2,44,45.

Study protocol

After providing informed consent, each participant underwent 2-week screening process to assess the ability to record the food diary and whether the participant can comply with the study protocol. The instructions were given for recording a food diary to assess individuals’ ability to track food intake. Patients had to record food diary of 3 days (2 days during Monday to Friday and 1 day from Saturday or Sunday). Within 2 weeks after the screening visit, patients were randomized by the nQquery Advisor 6.01 (Statistical Solutions Ltd., Saugus, MA, USA) into 2 groups: a “diet intervention” group and a “usual diet” group. Random allocation sequence was kept by a research assistant as the sequential numbered code that could not be reached by the research nurse and investigators. The research nurse explains the study to the participants, enroll and consent, and assign the participants to the intervention.

Diet intervention

Participants in diet intervention group received food with 3G rice from investigators. The food was delivered to the participants on a daily basis. Patients in the usual diet group have to consume their own food based on white rice. However, nutritional counseling was provided in both groups. Negative caloric balance was applied in both groups which is included in the provided food in the diet intervention group and included in the nutritional counseling in usual care group.

The total daily caloric intake prescribed for each participant was personalized. The caloric requirement calculations were based on the recommendations of the Dietary Reference Intake for Thais (year 2020) and considered an individual’s age, sex, body weight, and daily activity level46. The carbohydrate to protein to fat ratio was maintained at 45–50:20–30:20–35, with a minimum daily protein intake of 1.2 g/kg of body weight and at least 14 g of fiber per 1000 cal. With obese patients, the goal was to achieve a daily negative energy balance of 400–500 kcal46,47.

Participants in the diet intervention group were instructed to consume only the food prescribed by the investigators. The intervention involved a carbohydrate-based dietary product named “3G rice,” a mix of 3 rice varieties with a combined GI of 5223. Additionally, they were requested to limit snacks to less than 100 kcal daily. An investigator (WT) calculated the caloric requirement of each patient and instructed the product preparation team on the corresponding personalized meals. A daily meal package was delivered to the diet intervention participants once daily.

Participants in the usual diet group received standard diet and healthy lifestyle education. It included information on a diet with low cholesterol, low sugar, and low salt and instructions on maintaining a negative caloric balance for overweight or obese patients. However, the participants did not receive food provisions. The diet suggestions were based on the food consumption recommendations of the Dietary Reference Intake for Thais46.

Both groups received basic diet education and weight reduction education for obese patients. A nurse from the research team made telephone contact every 2 weeks with participants in the 2 groups to inquire about the weekly food intake and provide diet education. In the case of the diet intervention group, the nurse also monitored the degree of compliance with the intervention, and recorded the type and number of extra snacks.

The food diary record was a self-reported account of all foods and beverages consumed by each participant over 3 consecutive days. These data were analyzed with INMUCAL Nutrients software (version 4.0; Mahidol University, Bangkok, Thailand) to determine the quantities of various food components. The food diary data were analyzed at baseline (during screening and before randomization), at 6 weeks, and upon program completion (12 weeks after randomization).

Nutritional counseling

The nutritional counseling of the usual diet group contains the content of diet sugar control, increase consumption of vegetable and fruit, and the instruction for a weight reduction of 5–10% or negative caloric balance of 400–500 kcal for those who are overweight or obese (99% of the study population were overweight or obese) with the information on daily caloric requirement. The participants need to arrange the diet for their own.

The nutritional counseling for the diet intervention group provides a similar instruction as in the usual diet group plus but the investigators made the diet and send to the participants on daily delivery focus on high fiber low salt, and negative caloric balance of 400–500 kcal. The caloric requirement calculations were based on the recommendations of the Dietary Reference Intake for Thais (year 2020)46 and considered an individual’s age, sex, body weight, and daily activity level.

Image acquisition

Images for VAT assessment

We utilized the Philips Ingenia 3 T 3D 2-point Dixon gradient echo volumetric interpolated breath-hold examination technique in breath-hold mode. The acquisition sequence settings were as follows: axial plane matrix size, 400 × 352; resolution, 1 × 1 mm2; repetition time, 5.2 ms; echo time (TE) 1, 1.96 ms; TE2, 3.3 ms; number of slices, 5; slice thickness, 5 mm; distance factor, 10%; section gap, 0.5 mm; and acquisition time, 16 s. The acquisition focused on the intervertebral disk between lumbar vertebrae levels L2 and L3, covering the region from mid-L2 to mid-L3.

Images for hepatic fat assessment

The mDIXON Quant method utilized a 6-echo 3D gradient echo sequence with the following parameters: repetition time, 10 ms; TE1, 7.5 ms; ΔTE, 1.25 ms; fly back, none; echo train length, 6; water fat shift, 0.309 pixels; field of view, 400 × 350 mm; acquisition matrix size, 1.75 × 1.75 mm; reconstruction matrix size, 0.78 × 0.78 mm; slice thickness, 2.5 mm; and total acquisition time, 19 s. To avoid T1 saturation, a very low flip angle of only 3° was applied.

Image analysis

Visceral fat image analysis was performed using ImageJ software (version 1.53 k; National Institutes of Health, Bethesda, MD, USA). The adipose area was semiautomatically obtained after contour drawing with the automatic thresholding method, and the area was provided in square millimeters (Supplementary Fig. 1). The areas of superficial subcutaneous adipose tissue, deep subcutaneous adipose tissue, and VAT were averaged for 3 slices obtained from the same acquisition images.

The hepatic fat analysis utilized the 3-point IDEAL Dixon method and was quantified with semiautomatic Hippo Fat software. The hepatic fat percentage was calculated using the following formula:Hepaticfatpercentage=SIfatSIfat+SIwater×100

where SIfat and SIwater represent the averaged signal intensity on the reconstructed fat and water images, respectively. Images were independently analyzed by 1 radiological technologist with more than 10-year experience blinded to the intervention group who documented the percentage of fat in all 8 hepatic segments using a circular region of interest of 200–300 mm2 in area. A larger region of interest (800–1600 mm2) was obtained for the right and left lobes of the liver. Care was taken to select only representative regions while avoiding blood vessels or regions with artifacts.

Record of physical activity

We recorded physical activity by Mi Smart Band 6 (Xiaomi Communications Co., Ltd., Hefei City, China) for the whole duration of the study. The heart rate data was recorded every minute. We calculated the duration that participants spend on moderate and vigorous intensity based on the recommendation of ESC in the 2021 ESC cardiovascular prevention guideline (moderate and vigorous intensity = heart rate 64–76% and > 76% of predicted maximal heart rate, respectively)48. Step count per day was also recorded.

Data collection

The following data were collected at baseline and after 12 weeks of diet intervention: age, sex, body weight, height, BMI, waist circumference, blood pressure, and heart rate. Clinical laboratory tests included fasting plasma glucose, hemoglobin A1C, lipid profile, alanine aminotransferase, serum creatinine, electrolyte levels, and serum uric acid.

Outcomes

The primary outcomes, evaluated at the 12-week mark of the diet intervention, were changes in VAT area and percentage of hepatic fat. Secondary outcomes were changes in body weight, BMI, and blood chemistry.

Statistical analysis

Descriptive statistics were analyzed and presented as the means and standard deviations for continuous data and numbers and percentages for categorical data. Continuous data were compared using Student’s t-test for unpaired data, while categorical data were analyzed using the chi-square or Fisher’s exact tests. Paired t-tests were used to compare changes in the primary and secondary outcome variables between baseline and 12 weeks. The association between the intervention and primary outcomes was assessed using a linear regression model adjusted for the baseline results of each outcome. Similar analyses were conducted for the associations between the intervention and body weight or BMI.

Sensitivity analysis was performed by (1) analyzing the interaction of obesity and diabetes on the study outcomes, (2) analyzing the percentage changes in clinical outcomes to determine whether changes in body weight explained the changes in VAT area and hepatic fat, and (3) comparing changes in hepatic fat grades at 12 weeks relative to baseline. Hepatic fat was graded as class 1 (“normal”; < 6.4%), class 2 (“mild”; 6.4%–17.4%), class 3 (“moderate”; (17.4%–22.1%), and class 4 (“severe”; ≥ 22.1%)49. The use of threshold of 6.4% was based on the result of a previous study comparing percentage of hepatic fat compared to histopathology49. The threshold of 6.4% had 86% sensitivity and 83% specificity to diagnose grade 1 or higher steatosis compared to the histopathology. Sensitivity analysis based on VAT grading was not performed due to the lack of a universally accepted grading system for visceral fat. We also performed additional analysis to determine whether the effect of diet intervention on visceral fat and hepatic fat change independent on body weight change by adjusting the effect of diet intervention on outcomes adjusting for body weight change.

The analyses were performed using IBM SPSS Statistics (IBM Corp, Armonk, NY, USA). P values < 0.05 were deemed statistically significant. The p-values were adjusted for multiple comparison testing for the analysis between groups (diet intervention vs. usual diet) of these two outcomes (VAT and hepatic fat) with the use of significant p-value at p < 0.025.

Supplementary Information

Supplementary Figure 1.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72246-w.

Acknowledgements

The authors gratefully acknowledge Poom Sairat, BSc, for statistical analysis and data management.

Author contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All authors reviewed the manuscript.

Funding

This study received research funding from the National Research Council of Thailand (322/2564). The funding source did not influence any aspect of this study or the decision of the authors to submit this manuscript for publication.

Data availability

The dataset used to support the results and conclusions of this study is included within the manuscript. Additional data are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Powell-Wiley TM Obesity and cardiovascular disease: A scientific statement from the American heart association Circulation 2021 143 e984 e1010 10.1161/CIR.0000000000000973 33882682
Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: A scientific statement from the American heart association. Circulation 143, e984–e1010. 10.1161/CIR.0000000000000973 (2021).33882682 10.1161/CIR.0000000000000973
2. Ma CX Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management Cardiovasc. Diabetol. 2022 21 74 10.1186/s12933-022-01516-6 35568946
Ma, C. X. et al. Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management. Cardiovasc. Diabetol. 21, 74. 10.1186/s12933-022-01516-6 (2022).35568946 10.1186/s12933-022-01516-6
3. Abraham TM Pedley A Massaro JM Hoffmann U Fox CS Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors Circulation 2015 132 1639 1647 10.1161/CIRCULATIONAHA.114.015000 26294660
Abraham, T. M., Pedley, A., Massaro, J. M., Hoffmann, U. & Fox, C. S. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 132, 1639–1647. 10.1161/CIRCULATIONAHA.114.015000 (2015).26294660 10.1161/CIRCULATIONAHA.114.015000
4. Tatsumi Y Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: A cross-sectional study in Japan BMJ Open 2017 7 e013831 10.1136/bmjopen-2016-013831 28093438
Tatsumi, Y. et al. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: A cross-sectional study in Japan. BMJ Open 7, e013831. 10.1136/bmjopen-2016-013831 (2017).28093438 10.1136/bmjopen-2016-013831
5. Despres JP Body fat distribution and risk of cardiovascular disease: an update Circulation 2012 126 1301 1313 10.1161/CIRCULATIONAHA.111.067264 22949540
Despres, J. P. Body fat distribution and risk of cardiovascular disease: an update. Circulation 126, 1301–1313. 10.1161/CIRCULATIONAHA.111.067264 (2012).22949540 10.1161/CIRCULATIONAHA.111.067264
6. Lim S Taskinen MR Boren J Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome Obes. Rev. 2019 20 599 611 10.1111/obr.12820 30589487
Lim, S., Taskinen, M. R. & Boren, J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes. Rev. 20, 599–611. 10.1111/obr.12820 (2019).30589487 10.1111/obr.12820
7. Wallach JD Updating insights into rosiglitazone and cardiovascular risk through shared data: Individual patient and summary level meta-analyses BMJ 2020 368 l7078 10.1136/bmj.l7078 32024657
Wallach, J. D. et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: Individual patient and summary level meta-analyses. BMJ 368, l7078. 10.1136/bmj.l7078 (2020).32024657 10.1136/bmj.l7078
8. Bramante CT Raatz S Bomberg EM Oberle MM Ryder JR Cardiovascular risks and benefits of medications used for weight loss Front. Endocrinol. (Lausanne) 2019 10 883 10.3389/fendo.2019.00883 32010059
Bramante, C. T., Raatz, S., Bomberg, E. M., Oberle, M. M. & Ryder, J. R. Cardiovascular risks and benefits of medications used for weight loss. Front. Endocrinol. (Lausanne) 10, 883. 10.3389/fendo.2019.00883 (2019).32010059 10.3389/fendo.2019.00883
9. Cameron D Ubels J Norstrom F On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review Glob. Health Action 2018 11 1447828 10.1080/16549716.2018.1447828 29564962
Cameron, D., Ubels, J. & Norstrom, F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob. Health Action 11, 1447828. 10.1080/16549716.2018.1447828 (2018).29564962 10.1080/16549716.2018.1447828
10. Galaviz KI Narayan KMV Lobelo F Weber MB Lifestyle and the prevention of type 2 diabetes: A status report Am. J. Lifestyle Med. 2018 12 4 20 10.1177/1559827615619159 30202378
Galaviz, K. I., Narayan, K. M. V., Lobelo, F. & Weber, M. B. Lifestyle and the prevention of type 2 diabetes: A status report. Am. J. Lifestyle Med. 12, 4–20. 10.1177/1559827615619159 (2018).30202378 10.1177/1559827615619159
11. O’Donoghue G Lifestyle interventions to improve glycemic control in adults with type 2 diabetes living in low-and-middle income countries: A systematic review and meta-analysis of randomized controlled trials (RCTs) Int. J. Environ. Res. Public Health 2021 10.3390/ijerph18126273 34769529
O’Donoghue, G. et al. Lifestyle interventions to improve glycemic control in adults with type 2 diabetes living in low-and-middle income countries: A systematic review and meta-analysis of randomized controlled trials (RCTs). Int. J. Environ. Res. Public Health10.3390/ijerph18126273 (2021).34769529 10.3390/ijerph18126273
12. Xue Y The association between the dietary pattern in abdominal obesity based on visceral fat index and dyslipidaemia in the henan rural cohort study Br. J. Nutr. 2022 128 762 769 10.1017/S0007114521003640 34511145
Xue, Y. et al. The association between the dietary pattern in abdominal obesity based on visceral fat index and dyslipidaemia in the henan rural cohort study. Br. J. Nutr. 128, 762–769. 10.1017/S0007114521003640 (2022).34511145 10.1017/S0007114521003640
13. Anania C Perla FM Olivero F Pacifico L Chiesa C Mediterranean diet and nonalcoholic fatty liver disease World J. Gastroenterol. 2018 24 2083 2094 10.3748/wjg.v24.i19.2083 29785077
Anania, C., Perla, F. M., Olivero, F., Pacifico, L. & Chiesa, C. Mediterranean diet and nonalcoholic fatty liver disease. World J. Gastroenterol. 24, 2083–2094. 10.3748/wjg.v24.i19.2083 (2018).29785077 10.3748/wjg.v24.i19.2083
14. Bendall CL Central obesity and the mediterranean diet: A systematic review of intervention trials Crit. Rev. Food Sci. Nutr. 2018 58 3070 3084 10.1080/10408398.2017.1351917 29039967
Bendall, C. L. et al. Central obesity and the mediterranean diet: A systematic review of intervention trials. Crit. Rev. Food Sci. Nutr. 58, 3070–3084. 10.1080/10408398.2017.1351917 (2018).29039967 10.1080/10408398.2017.1351917
15. Galan-Lopez P Association between adherence to the mediterranean diet and physical fitness with body composition parameters in 1717 European Adolescents: The adoleshealth study Nutrients 2019 10.3390/nu12010077 31892139
Galan-Lopez, P. et al. Association between adherence to the mediterranean diet and physical fitness with body composition parameters in 1717 European Adolescents: The adoleshealth study. Nutrients10.3390/nu12010077 (2019).31892139 10.3390/nu12010077
16. Mogre V Nyaba R Aleyira S Sam NB Demographic, dietary and physical activity predictors of general and abdominal obesity among university students: A cross-sectional study Springerplus 2015 4 226 10.1186/s40064-015-0999-2 26140255
Mogre, V., Nyaba, R., Aleyira, S. & Sam, N. B. Demographic, dietary and physical activity predictors of general and abdominal obesity among university students: A cross-sectional study. Springerplus 4, 226. 10.1186/s40064-015-0999-2 (2015).26140255 10.1186/s40064-015-0999-2
17. Look ARG Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N. Engl. J. Med. 2013 369 145 154 10.1056/NEJMoa1212914 23796131
Look, A. R. G. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145–154. 10.1056/NEJMoa1212914 (2013).23796131 10.1056/NEJMoa1212914
18. Hemmingsen B Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus Cochrane Database Syst. Rev. 2017 12 CD003054 10.1002/14651858.CD003054.pub4 29205264
Hemmingsen, B. et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst. Rev. 12, CD003054. 10.1002/14651858.CD003054.pub4 (2017).29205264 10.1002/14651858.CD003054.pub4
19. Jung SH Ha KH Kim DJ Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults Yonsei Med. J. 2016 57 674 680 10.3349/ymj.2016.57.3.674 26996568
Jung, S. H., Ha, K. H. & Kim, D. J. Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. Yonsei Med. J. 57, 674–680. 10.3349/ymj.2016.57.3.674 (2016).26996568 10.3349/ymj.2016.57.3.674
20. Cesaro A Visceral adipose tissue and residual cardiovascular risk: A pathological link and new therapeutic options Front. Cardiovasc. Med. 2023 10 1187735 10.3389/fcvm.2023.1187735 37576108
Cesaro, A. et al. Visceral adipose tissue and residual cardiovascular risk: A pathological link and new therapeutic options. Front. Cardiovasc. Med. 10, 1187735. 10.3389/fcvm.2023.1187735 (2023).37576108 10.3389/fcvm.2023.1187735
21. Ismaiel A Dumitrascu DL How to reduce cardiovascular risk in nonalcoholic fatty liver disease Am. J. Ther. 2023 30 e242 e256 10.1097/MJT.0000000000001174 32467498
Ismaiel, A. & Dumitrascu, D. L. How to reduce cardiovascular risk in nonalcoholic fatty liver disease. Am. J. Ther. 30, e242–e256. 10.1097/MJT.0000000000001174 (2023).32467498 10.1097/MJT.0000000000001174
22. Nounmusig J The effect of low and high glycemic index based rice varieties in test meals on postprandial blood glucose, insulin and incretin hormones response in prediabetic subjects Int. Food Res. J. 2018 25 835 841
Nounmusig, J. et al. The effect of low and high glycemic index based rice varieties in test meals on postprandial blood glucose, insulin and incretin hormones response in prediabetic subjects. Int. Food Res. J. 25, 835–841 (2018).
23. Li Yan C In-Vivo Glycemic Index Determination of Natural Organic 3G Rice 2018 Innovation and Resource Center, Singapore Polytechnic
Li Yan, C. In-Vivo Glycemic Index Determination of Natural Organic 3G Rice (Innovation and Resource Center, Singapore Polytechnic, 2018).
24. Lee JJ Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: The framingham heart study Am. J. Med. 2018 131 684 692 10.1016/j.amjmed.2018.02.002 29518370
Lee, J. J. et al. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: The framingham heart study. Am. J. Med. 131, 684–692. 10.1016/j.amjmed.2018.02.002 (2018).29518370 10.1016/j.amjmed.2018.02.002
25. Engin A Endothelial dysfunction in obesity Adv. Exp. Med. Biol. 2017 960 345 379 10.1007/978-3-319-48382-5_15 28585207
Engin, A. Endothelial dysfunction in obesity. Adv. Exp. Med. Biol. 960, 345–379. 10.1007/978-3-319-48382-5_15 (2017).28585207 10.1007/978-3-319-48382-5_15
26. Ndumele CE Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation Arterioscler. Thromb. Vasc. Biol. 2011 31 1927 1932 10.1161/ATVBAHA.111.228262 21546603
Ndumele, C. E. et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1927–1932. 10.1161/ATVBAHA.111.228262 (2011).21546603 10.1161/ATVBAHA.111.228262
27. Huffman MD Incidence of cardiovascular risk factors in an Indian urban cohort results from the New Delhi birth cohort J. Am. Coll. Cardiol. 2011 57 1765 1774 10.1016/j.jacc.2010.09.083 21511113
Huffman, M. D. et al. Incidence of cardiovascular risk factors in an Indian urban cohort results from the New Delhi birth cohort. J. Am. Coll. Cardiol. 57, 1765–1774. 10.1016/j.jacc.2010.09.083 (2011).21511113 10.1016/j.jacc.2010.09.083
28. Raji A Seely EW Arky RA Simonson DC Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians J. Clin. Endocrinol. Metab. 2001 86 5366 5371 10.1210/jcem.86.11.7992 11701707
Raji, A., Seely, E. W., Arky, R. A. & Simonson, D. C. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J. Clin. Endocrinol. Metab. 86, 5366–5371. 10.1210/jcem.86.11.7992 (2001).11701707 10.1210/jcem.86.11.7992
29. Funtikova AN Mediterranean diet impact on changes in abdominal fat and 10-year incidence of abdominal obesity in a Spanish population Br. J. Nutr. 2014 111 1481 1487 10.1017/S0007114513003966 24382017
Funtikova, A. N. et al. Mediterranean diet impact on changes in abdominal fat and 10-year incidence of abdominal obesity in a Spanish population. Br. J. Nutr. 111, 1481–1487. 10.1017/S0007114513003966 (2014).24382017 10.1017/S0007114513003966
30. Tosti V Bertozzi B Fontana L Health benefits of the mediterranean diet: Metabolic and molecular mechanisms J. Gerontol. A Biol. Sci. Med. Sci. 2018 73 318 326 10.1093/gerona/glx227 29244059
Tosti, V., Bertozzi, B. & Fontana, L. Health benefits of the mediterranean diet: Metabolic and molecular mechanisms. J. Gerontol. A Biol. Sci. Med. Sci. 73, 318–326. 10.1093/gerona/glx227 (2018).29244059 10.1093/gerona/glx227
31. Barber TM Kabisch S Pfeiffer AFH Weickert MO The health benefits of dietary fibre Nutrients 2020 10.3390/nu12103209 33096647
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H. & Weickert, M. O. The health benefits of dietary fibre. Nutrients10.3390/nu12103209 (2020).33096647 10.3390/nu12103209
32. Malavolti M Sodium and potassium content of foods consumed in an Italian population and the impact of adherence to a mediterranean diet on their intake Nutrients 2021 10.3390/nu13082681 34444841
Malavolti, M. et al. Sodium and potassium content of foods consumed in an Italian population and the impact of adherence to a mediterranean diet on their intake. Nutrients10.3390/nu13082681 (2021).34444841 10.3390/nu13082681
33. Forouhi NG Embracing complexity: Making sense of diet, nutrition, obesity and type 2 diabetes Diabetologia 2023 66 786 799 10.1007/s00125-023-05873-z 36786838
Forouhi, N. G. Embracing complexity: Making sense of diet, nutrition, obesity and type 2 diabetes. Diabetologia 66, 786–799. 10.1007/s00125-023-05873-z (2023).36786838 10.1007/s00125-023-05873-z
34. Despres JP What is "metabolically healthy obesity"?: From epidemiology to pathophysiological insights J. Clin. Endocrinol. Metab. 2012 97 2283 2285 10.1210/jc.2012-2081 22774209
Despres, J. P. What is “metabolically healthy obesity”?: From epidemiology to pathophysiological insights. J. Clin. Endocrinol. Metab. 97, 2283–2285. 10.1210/jc.2012-2081 (2012).22774209 10.1210/jc.2012-2081
35. Schwingshackl L Morze J Hoffmann G Mediterranean diet and health status: Active ingredients and pharmacological mechanisms Br. J. Pharmacol. 2020 177 1241 1257 10.1111/bph.14778 31243760
Schwingshackl, L., Morze, J. & Hoffmann, G. Mediterranean diet and health status: Active ingredients and pharmacological mechanisms. Br. J. Pharmacol. 177, 1241–1257. 10.1111/bph.14778 (2020).31243760 10.1111/bph.14778
36. Tapsell LC Foods and food components in the Mediterranean diet: Supporting overall effects BMC Med. 2014 12 100 10.1186/1741-7015-12-100 24935157
Tapsell, L. C. Foods and food components in the Mediterranean diet: Supporting overall effects. BMC Med. 12, 100. 10.1186/1741-7015-12-100 (2014).24935157 10.1186/1741-7015-12-100
37. Costabile G Effects on cardiovascular risk factors of a low- vs high-glycemic index Mediterranean diet in high cardiometabolic risk individuals: The MEDGI-Carb study Eur. J. Clin. Nutr. 2024 78 384 390 10.1038/s41430-024-01406-y 38267533
Costabile, G. et al. Effects on cardiovascular risk factors of a low- vs high-glycemic index Mediterranean diet in high cardiometabolic risk individuals: The MEDGI-Carb study. Eur. J. Clin. Nutr. 78, 384–390. 10.1038/s41430-024-01406-y (2024).38267533 10.1038/s41430-024-01406-y
38. Khalafi M The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis Diabetes Obes. Metab. 2024 26 3830 3841 10.1111/dom.15730 38956175
Khalafi, M. et al. The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes. Metab. 26, 3830–3841. 10.1111/dom.15730 (2024).38956175 10.1111/dom.15730
39. Song DK Kim YW Beneficial effects of intermittent fasting: A narrative review J. Yeungnam Med. Sci. 2023 40 4 11 10.12701/jyms.2022.00010 35368155
Song, D. K. & Kim, Y. W. Beneficial effects of intermittent fasting: A narrative review. J. Yeungnam Med. Sci. 40, 4–11. 10.12701/jyms.2022.00010 (2023).35368155 10.12701/jyms.2022.00010
40. Harris E Study examines intermittent fasting and cardiovascular mortality JAMA 2024 331 1440 10.1001/jama.2024.5158 38607647
Harris, E. Study examines intermittent fasting and cardiovascular mortality. JAMA 331, 1440. 10.1001/jama.2024.5158 (2024).38607647 10.1001/jama.2024.5158
41. Hunter GR Gower BA Kane BL Age related shift in visceral fat Int. J. Body Compos. Res. 2010 8 103 108 24834015
Hunter, G. R., Gower, B. A. & Kane, B. L. Age related shift in visceral fat. Int. J. Body Compos. Res. 8, 103–108 (2010).24834015
42. Lin Y Age patterns of nonalcoholic fatty liver disease incidence: Heterogeneous associations with metabolic changes Diabetol. Metab. Syndr. 2022 14 181 10.1186/s13098-022-00930-w 36443867
Lin, Y. et al. Age patterns of nonalcoholic fatty liver disease incidence: Heterogeneous associations with metabolic changes. Diabetol. Metab. Syndr. 14, 181. 10.1186/s13098-022-00930-w (2022).36443867 10.1186/s13098-022-00930-w
43. Nagao T Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial J. Nutr. 2000 130 792 797 10.1093/jn/130.4.792 10736331
Nagao, T. et al. Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. J. Nutr. 130, 792–797. 10.1093/jn/130.4.792 (2000).10736331 10.1093/jn/130.4.792
44. World Health Organization: The Asia-Pacific perspective : redefining obesity and its treatment: World Health Organization. Regional Office for the Western, Pacific. Coordinated by the International Diabetes Institute ; co-sponsored jointly by the Regional Office for the Western Pacific (WPRO), World Health Organization, the International Association for the Study of Obesity and the International Obesity Task Force (Sydney : Health Communications Australia, 2000).
45. Organization WH Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 2004 363 157 163 10.1016/S0140-6736(03)15268-3 14726171
Organization, W. H. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163. 10.1016/S0140-6736(03)15268-3 (2004).14726171 10.1016/S0140-6736(03)15268-3
46. Dietary reference intake for Thais: Thai Dietetic Association, https://www.thaidietetics.org/wp-content/uploads/2020/04/dri2563.pdf (2020).
47. The HHS Office of Disease Prevention and Health Promotion (ODPHP), a. t. U. C. f. N. P. a. P. C. Dietary Guidelines for Americans, <https://www.dietaryguidelines.gov/> (2020–2025 ).
48. Visseren FLJ ESC Guidelines on cardiovascular disease prevention in clinical practice Eur Heart J 2021 42 3227 3337 10.1093/eurheartj/ehab484 34458905
Visseren, F. L. J. et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42, 3227–3337. 10.1093/eurheartj/ehab484 (2021).34458905 10.1093/eurheartj/ehab484
49. Tang A Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease Radiology 2015 274 416 425 10.1148/radiol.14140754 25247408
Tang, A. et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274, 416–425. 10.1148/radiol.14140754 (2015).25247408 10.1148/radiol.14140754
